retatrutide clinical trials brazil 🚨Breaking: Retatrutide's first Phase 3 T2D data just dropped. ▸ A1C: −2.0% at 40 weeks ▸ Weight: −36.6 lbs (−16.8%) at 12 mg ▸ No weight loss plateau — curve still descending Retatrutide ("Reta") Is Trending on

Placing retatrutide in the broader context of obesity treatment is crucial

Safety and efficacy of semaglutide added to Japanese patients with insulin-treated type 2 diabetes: A randomized, placebo-controlled, double-blind trial (SUSTAIN Japan)

Picked particles were extracted and 2D classified using RELION (version 3.0.7)

The same pattern applies to body aches sometimes reported with tirzepatide , which can mimic the systemic symptoms of a more advanced UTI

And in June 2026, the first dedicated diabetes Phase 3 trial (TRANSCEND-T2D-1) confirmed 16.8% weight loss alongside -2.0% HbA1c reduction in 537 type 2 diabetes patients